Genome-wide approaches to systematically identify substrates of the ubiquitin-proteasome pathway

Trends in Biotechnology

Volumn 28, Issue 9, 2010, Pages 461-467

  Liu, Chang ^a   Choe, Vitnary ^a   Rao, Hai ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEGRADATION PATHWAYS; DRUG TARGETS; HUMAN DISEASE; MULTIPLE MYELOMA; NEURODEGENERATIVE DISORDERS; PROTEASOME INHIBITORS; PROTEASOMES; UBIQUITIN; UBIQUITIN-PROTEASOME SYSTEM;

DEGRADATION; GENES;

PROTEINS;

APC PROTEIN; F BOX PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN CUL1; REGULATOR PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

BINDING KINETICS; CARCINOMA; CELL CYCLE REGULATION; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG TARGETING; ENDOCYTOSIS; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; EUKARYOTE; F BOX MOTIF; GENE EXPRESSION; GENETIC REGULATION; GENOME ANALYSIS; HEART DEVELOPMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIDDLE SYNDROME; MOLECULAR MECHANICS; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; UBIQUITINATION; YEAST;

FUNGAL PROTEINS; GENOMICS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EUKARYOTA;

EID: 77955842254     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2010.06.003     Document Type: Review

References (72)

1. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
2. Hochstrasser M. Introduction to intracellular protein degradation. Chem. Rev. 2009, 109:1479-1480.
3. Navon A., Ciechanover A. The 26S proteasome: from basic mechanisms to drug targeting. J. Biol. Chem. 2009, 284:33713-33718.
4. Bedford L., et al. The UPS and autophagy in chronic neurodegenerative disease: six of one and half a dozen of the other - or not?. Autophagy 2009, 5:224-227.
5. Hoeller D., Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009, 458:438-444.
6. Dikic I., et al. Ubiquitin-binding domains - from structures to functions. Nat. Rev. Mol. Cell Biol. 2009, 10:659-671.
7. Skaug B., Chen Z.J. SUMO, Ubiquitin, UBL Proteins: Implications for Human Diseases - fifth international conference. IDrugs 2010, 13:224-227.
8. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 2009, 78:477-513.
9. Rao H., et al. Degradation of a cohesin subunit by the N-end rule pathway is essential for chromosome stability. Nature 2001, 410:955-959.
10. Varshavsky A. Regulated protein degradation. Trends Biochem. Sci. 2005, 30:283-286.
11. Sriram S.M., et al. Multivalency-assisted control of intracellular signaling pathways: application for ubiquitin-dependent N-end rule pathway. Chem. Biol. 2009, 16:121-131.
12. Hitchcock A.L., et al. A subset of membrane-associated proteins is ubiquitinated in response to mutations in the endoplasmic reticulum degradation machinery. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12735-12740.
13. Kirkpatrick D.S., et al. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nat. Cell Biol. 2005, 7:750-757.
14. Mayor T., et al. Quantitative profiling of ubiquitylated proteins reveals proteasome substrates and the substrate repertoire influenced by the Rpn10 receptor pathway. Mol. Cell. Proteomics 2007, 6:1885-1895.
15. Wang X., et al. Proteomics of proteasome complexes and ubiquitinated proteins. Expert Rev. Proteomics 2007, 4:649-665.
16. Xu P., Peng J. Dissecting the ubiquitin pathway by mass spectrometry. Biochim. Biophys. Acta 2006, 1764:1940-1947.
17. Xu P., Peng J. Characterization of polyubiquitin chain structure by middle-down mass spectrometry. Anal. Chem. 2008, 80:3438-3444.
18. Jadhav T., Wooten M.W. Defining an embedded code for protein ubiquitination. J. Proteomics Bioinform. 2009, 2:316.
19. Saracco S.A., et al. Tandem affinity purification and mass spectrometric analysis of ubiquitylated proteins in Arabidopsis. Plant J. 2009, 59:344-358.
20. van Roessel P., et al. Independent regulation of synaptic size and activity by the anaphase-promoting complex. Cell 2004, 119:707-718.
21. Ravid T., Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat. Rev. Mol. Cell Biol. 2008, 9:679-690.
22. Cardozo T., Pagano M. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes. BMC Biochem. 2007, 8(Suppl. 1):S9.
23. Reed S.I. Deathproof: new insights on the role of Skp2 in tumorigenesis. Cancer Cell 2008, 13:88-89.
24. Skaar J.R., Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr. Opin. Cell Biol. 2009, 21:816-824.
25. Akhoondi S., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007, 67:9006-9012.
26. Li M., Zhang P. The function of APC/CCdh1 in cell cycle and beyond. Cell Div. 2009, 4:2.
27. Zenker M., et al. Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation (Johanson-Blizzard syndrome). Nat. Genet. 2005, 37:1345-1350.
28. Rotin D., Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2009, 10:398-409.
29. Rotin D. Role of the UPS in Liddle syndrome. BMC Biochem. 2008, 9(Suppl. 1):S5.
30. + channel (ENaC) by ubiquitination. EMBO J. 1997, 16:6325-6336.
31. + channel. FASEB J. 2001, 15:204-214.
32. Fouladkou F., et al. The ubiquitin ligase Nedd4-1 is required for heart development and is a suppressor of thrombospondin-1. J. Biol. Chem. 2010, 285:6770-6780.
33. Kawabe H., et al. Regulation of Rap2A by the ubiquitin ligase Nedd4-1 controls neurite development. Neuron 2010, 65:358-372.
34. Drinjakovic J., et al. E3 ligase Nedd4 promotes axon branching by downregulating PTEN. Neuron. 2010, 65:341-357.
35. Kishi T., et al. A refined two-hybrid system reveals that SCF (Cdc4)-dependent degradation of Swi5 contributes to the regulatory mechanism of S-phase entry. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14497-14502.
36. Zhu H., et al. Global analysis of protein activities using proteome chips. Science 2001, 293:2101-2105.
37. Yu H., et al. High-quality binary protein interaction map of the yeast interactome network. Science 2008, 322:104-110.
38. Kung L.A., et al. Global analysis of the glycoproteome in Saccharomyces cerevisiae reveals new roles for protein glycosylation in eukaryotes. Mol. Syst. Biol. 2009, 5:308.
39. Fasolo J., Snyder M. Protein microarrays. Methods Mol. Biol. 2009, 548:209-222.
40. Hesselberth J.R., et al. Comparative analysis of Saccharomyces cerevisiae WW domains and their interacting proteins. Genome Biol. 2006, 7:R30.
41. Gupta R., et al. Ubiquitination screen using protein microarrays for comprehensive identification of Rsp5 substrates in yeast. Mol. Syst. Biol. 2007, 3:116.
42. Persaud A., et al. Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol. Syst. Biol. 2009, 5:333.
43. Lu J.Y., et al. Functional dissection of a HECT ubiquitin E3 ligase. Mol. Cell. Proteomics 2008, 7:35-45.
44. Merbl Y., Kirschner M.W. Large-scale detection of ubiquitination substrates using cell extracts and protein microarrays. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2543-2548.
45. Perroy J., et al. Real-time monitoring of ubiquitination in living cells by BRET. Nat. Methods 2004, 1:203-208.
46. Benanti J.A., et al. A proteomic screen reveals SCFGrr1 targets that regulate the glycolytic-gluconeogenic switch. Nat. Cell Biol. 2007, 9:1184-1191.
47. Yen H.C., et al. Global protein stability profiling in mammalian cells. Science 2008, 322:918-923.
48. Yen H.C., Elledge S.J. Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science 2008, 322:923-929.
49. Kirkpatrick D.S., Dixit V.M. GPS navigation of the protein-stability landscape. Nat. Biotechnol. 2009, 27:46-48.
50. Sopko R., et al. Mapping pathways and phenotypes by systematic gene overexpression. Mol. Cell 2006, 21:319-330.
51. Dixon S.J., et al. Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16653-16658.
52. Irniger S., et al. Genes involved in sister chromatid separation are needed for B-type cyclin proteolysis in budding yeast. Cell 1995, 81:269-278.
53. Liu C., et al. A genome-wide synthetic dosage lethality screen reveals multiple pathways that require the functioning of ubiquitin-binding proteins Rad23 and Dsk2. BMC Biol. 2009, 7:75.
54. Liu C., et al. Ubiquitin chain elongation enzyme Ufd2 regulates a subset of Doa10 substrates. J. Biol. Chem. 2010, 285:10265-10272.
55. Koegl M., et al. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999, 96:635-644.
56. Canaani D. Methodological approaches in application of synthetic lethality screening towards anticancer therapy. Br. J. Cancer 2009, 100:1213-1218.
57. Park B., et al. Use of gene dosage effects for a whole-genome screen to identify Mycobacterium marinum macrophage infection loci. Infect. Immun. 2008, 76:3100-3115.
58. Belle A., et al. Quantification of protein half-lives in the budding yeast proteome. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13004-13009.
59. Huttenhain R., et al. Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 2009, 13:518-525.
60. Picotti P., et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009, 138:795-806.
61. McNatt M.W., et al. Direct binding to Rsp5 mediates ubiquitin-independent sorting of Sna3 via the multivesicular body pathway. Mol. Biol. Cell 2007, 18:697-706.
62. Oestreich A.J., et al. Characterization of multiple multivesicular body sorting determinants within Sna3: a role for the ubiquitin ligase Rsp5. Mol. Biol. Cell 2007, 18:707-720.
63. Stawiecka-Mirota M., et al. Targeting of Sna3p to the endosomal pathway depends on its interaction with Rsp5p and multivesicular body sorting on its ubiquitylation. Traffic 2007, 8:1280-1296.
64. Watson H., Bonifacino J.S. Direct binding to Rsp5p regulates ubiquitination-independent vacuolar transport of Sna3p. Mol. Biol. Cell 2007, 18:1781-1789.
65. Carrano A.C., et al. A conserved ubiquitination pathway determines longevity in response to diet restriction. Nature 2009, 460:396-399.
66. Shakya R., et al. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7040-7045.
67. Sarge K.D., Park-Sarge O.K. Sumoylation and human disease pathogenesis. Trends Biochem. Sci. 2009, 34:200-205.
68. Harty R.N., et al. Antiviral activity of innate immune protein ISG15. J. Innate Immun. 2009, 1:397-404.
69. Leidel S., et al. Ubiquitin-related modifier Urm1 acts as a sulphur carrier in thiolation of eukaryotic transfer RNA. Nature 2009, 458:228-232.
70. Ohta T., et al. Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction. Breast Cancer 2009, 16:268-274.
71. Pankratz N., et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 2009, 73:279-286.
72. Wild P., Dikic I. Mitochondria get a Parkin' ticket. Nat. Cell Biol. 2010, 12:104-106.